Shukra Pharma wins rights to distribute Wockhardt advanced anti-infective formulations across India
Shukra Pharma wins rights to distribute Wockhardt advanced anti-infective formulations across India Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-09-11T12:15:00+05:30 | Updated On 11 Sept 2025 12:15 PM ISTNew Delhi: Wockhardt, a global pharma company, has authorised Shukra Pharma to represent, distribute, and manage its products across all ESIC/ESIS Hospitals, Defence Hospitals / AFMSD / DGAFMS units across India.On Wednesday, Shukra Pharmaceuticals said that it entered into a strategic non-exclusive Pan-India distribution arrangement with Wockhardt Ltd.According to an exchange filing, the authorization is effective from September 9, 2025 and is valid until March 2026.The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin), which are breakthrough antibiotics developed to combat critical infections. "The arrangement will strengthen the Company’s presence in institutional and government healthcare networks across India, enhance revenue visibility and operational footprint, create long-term value for shareholders by aligning with India’s expanding healthcare and hospital infrastructure," Shukra Pharma stated.Shukra Pharmaceuticals Limited is engaged in manufacturing and marketing pharmaceutical products as well as laboratory testing.Read also: Wockhardt to exit US generic pharmaceutical segmentwockhardtwockhardt newsshukra pharmaRuchika SharmaRuchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751Dr. Kamal Kant KohliDr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751Show Full ArticleNext Story